Updated daily
Drug recalls
Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.
Class IIOngoingNov 27, 2024Vitamin D3cGMP Deviations: Observations were made that some blister card-foils were separating from the blister cavity.Safecor Health, LLC · D-0056-2025Class IIOngoingNov 27, 2024XelstrymDefective Delivery System: The product does not meet predetermined specifications for Coldflow (adhesive).Noven Pharmaceuticals Inc · D-0055-2025Class IITerminatedNov 27, 2024Ramipril Capsules USP 10 mgCGMP Deviations: Active pharmaceutical ingredient was sourced from an unapproved vendorLupin Pharmaceuticals Inc. · D-0054-2025Class IITerminatedNov 27, 2024Ramipril Capsules USP 5 mgCGMP Deviations: Active pharmaceutical ingredient was sourced from an unapproved vendorLupin Pharmaceuticals Inc. · D-0053-2025Class IITerminatedNov 27, 2024Ramipril Capsules USP 2.5 mgCGMP Deviations: Active pharmaceutical ingredient was sourced from an unapproved vendorLupin Pharmaceuticals Inc. · D-0052-2025Class IITerminatedNov 27, 2024BEVACIZUMABLack of Sterility AssuranceTailstorm Health INC · D-0051-2025Class IITerminatedNov 27, 2024Guaifenesin Dextromethorphan SyrupFailed Impurity/Degradation SpecificationsThe Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories · D-0050-2025Class IITerminatedNov 27, 2024Guaifenesin Dextromethorphan SyrupFailed Impurity/Degradation SpecificationsThe Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories · D-0049-2025Class IIITerminatedNov 27, 2024Triamcinolone Acetonide Cream USPSubpotent and Superpotent Drug. Out of specification assay results recorded as part of Uniformity of Container test during long-term stability testing.Padagis US LLC · D-0048-2025Class IIIOngoingNov 27, 2024IBU (ibuprofen) 600 mg tabletsFailed Tablet/Capsule SpecificationsDr. Reddy's Laboratories, Inc. · D-0047-2025Class IIOngoingNov 20, 2024Perio Maintenance Rinse 0.63% Stannous Fluoride Concentrated SolutionSubpotent DrugKeystone Industries · D-0046-2025Class IIITerminatedNov 20, 2024Hydralazine HCl TabletsFailed Impurities/Degradation Specifications; during routine stability testing for impurities.The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories · D-0045-2025Class IIOngoingNov 20, 2024Lanthanum Carbonate Chewable TabletsFailed Tablet/Capsule Specifications: Complaints received of crushed and broken tablets.Cipla USA, Inc. · D-0044-2025Class IIOngoingNov 20, 2024Lanthanum Carbonate Chewable TabletsFailed Tablet/Capsule Specifications: Complaints received of crushed and broken tablets.Cipla USA, Inc. · D-0043-2025Class IIOngoingNov 20, 2024Trinity Gold NutritionMarketed without an Approved NDA/ANDA: FDA analysis found product to be tainted with undeclared acetaminophen, diclofenac and phenylbutazone.Trinity Gold Nutrition · D-0042-2025Class IIOngoingNov 13, 2024Ibuprofen 800mgFailed Impurities/Degradation Specifications: Product failed impurity specifications at the 18-month stability testing.Direct Rx · D-0041-2025Class ITerminatedNov 13, 2024Ascorbic Acid Inj. SolutionPresence of Particulate Matter: Presence of glass particulates.Staska Pharmaceuticals, Inc. · D-0040-2025Class IIOngoingNov 13, 2024Regadenoson InjectionLabeling: Missing LabelBaxter Healthcare Corporation · D-0039-2025Class IIOngoingNov 13, 2024Dapsone Gel 7.5%CrystallizationViona Pharmaceuticals Inc · D-0038-2025Class IIOngoingNov 13, 2024Morphine Sulfate Extended-Release Tablets 30 mgFailed Impurities/Degradation SpecificationDr. Reddy's Laboratories, Inc. · D-0037-2025Class IIOngoingNov 13, 2024Morphine Sulfate Extended-Release Tablets 15 mgFailed Impurities/Degradation SpecificationDr. Reddy's Laboratories, Inc. · D-0036-2025Class IIOngoingNov 13, 2024Timolol Maleate Ophthalmic Solution USPDefective Container: Unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottleFDC Limited · D-0035-2025Class IIIOngoingNov 13, 2024Kids' Cough and Chest CongestionCrystallization: Lack of uniformity - a change in texture, chunky, grainy, and small crystal substances inside the bottles.Denison Pharmaceuticals, LLC · D-0034-2025Class IIIOngoingNov 13, 2024Adult Cough and Chest CongestionCrystallization: Lack of uniformity - a change in texture, chunky, grainy, and small crystal substances inside the bottles.Denison Pharmaceuticals, LLC · D-0033-2025Class IITerminatedNov 6, 2024Cinacalcet TabletsCGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits.Accord Healthcare, Inc. · D-0032-2025Class IITerminatedNov 6, 2024Cinacalcet TabletsCGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits.Accord Healthcare, Inc. · D-0031-2025Class IITerminatedNov 6, 2024Cinacalcet Tablets 30 mgCGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits.Accord Healthcare, Inc. · D-0030-2025Class IITerminatedNov 6, 2024Chlorpheniramine Maleate 4 mg tabletsSuperpotent Drug: Stability failure for assay at 6 months test time-point.BLI International, Inc. · D-0029-2025Class IIOngoingNov 6, 2024Cinacalcet TabletsCGMP Deviations: Presence of N-nitroso Cinacalcet impurity above FDA recommended interim limitDr. Reddy's Laboratories, Inc. · D-0028-2025Class IIOngoingNov 6, 2024Cinacalcet TabletsCGMP Deviations: Presence of N-nitroso Cinacalcet impurity above FDA recommended interim limitDr. Reddy's Laboratories, Inc. · D-0027-2025Class IIOngoingNov 6, 2024Cinacalcet TabletsCGMP Deviations: Presence of N-nitroso Cinacalcet impurity above FDA recommended interim limitDr. Reddy's Laboratories, Inc. · D-0026-2025Class IIOngoingOct 30, 2024OneLAX Docusate Sodium LiquidCGMP DeviationsAkron Pharma, Inc. · D-0025-2025Class IIOngoingOct 30, 2024AK Forte Ortiga y Omega 3 Cont. Neto 100 TabletasMarketed without an Approved NDA/ANDA: FDA analysis found the product to be tainted with undeclared diclofenac and acetaminophen.C & A Naturistics · D-0024-2025Class IITerminatedOct 30, 2024Thiamine HCl 0.9% Sodium Chloride Injection USPcGMP violationsFresenius Kabi Compounding, LLC · D-0023-2025Class IITerminatedOct 30, 2024EPINEPHrine 0.9% Sodium Chloride Injection USPcGMP violationsFresenius Kabi Compounding, LLC · D-0022-2025Class IITerminatedOct 30, 2024Oxytocin 0.9% Sodium Chloride Injection USPcGMP violationsFresenius Kabi Compounding, LLC · D-0021-2025Class IITerminatedOct 30, 2024NORepinephrine Bitartrate 0.9% Sodium Chloride Injection USPcGMP violationsFresenius Kabi Compounding, LLC · D-0020-2025Class IITerminatedOct 30, 2024NORepinephrine Bitartrate 0.9% Sodium Chloride Injection USPcGMP violationsFresenius Kabi Compounding, LLC · D-0019-2025Class IITerminatedOct 30, 2024Vancomycin HCl 750 mg per 250 mL 0.9% Sodium Chloride Injection USPcGMP violationsFresenius Kabi Compounding, LLC · D-0018-2025Class IITerminatedOct 30, 2024Phenylephrine HCl 0.9% Sodium Chloride Injection USPcGMP violationsFresenius Kabi Compounding, LLC · D-0017-2025